Treatments that reduce nerve damage

Regenesance is a Dutch biotech company 	 dedicated to developing novel treatments for neurodegenerative disorders

Patients with neurodegenerative disorders have few therapeutic options. At Regenesance, we are developing therapeutic products that target the Complement system, part of the bodies immune system. Regenesance showed that in neurological disorders nerve regeneration is accelerated after inhibition of the Complement system.  Regenesance believes this approach will offer treatment opportunities to patients suffering from ALS and Mysthenia gravis.

First Therapeutic Product Focus: ALS

Regenesance is building a pipeline of monoclonal antibodies and small molecules products to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway.

Regenesance focuses on the development of the Orphan drug indications ALS (Amyotrophic Lateral Sclerosis) and Myasthenia Gravis. In a later stage also Multiple Sclerosis can be a well defined disease target.  

About Us

Regenesance was founded in November, 2009 on ground breaking research by its founder Prof. Baas and his team from the Academic Medical Center (AMC) at the University of Amsterdam in the Netherlands.

"Inhibition of Complement results in accelerated nerve regeneration in neurological disorders"


Latest News

View latest press releases and publications below in pdf format.

October 29 2012 | BIOCENTURY, emerging company profile (S. Hansen): Regenesance: Stopping the MAC attack.

May 7, 2012 | Regenesance and ALS-TDI partner to investigate a potential treatment for ALS patients.

January 25, 2012 | Nature Reviews Neuroscience , research highlights (S. Lewis), Neurodenerative disorders: Microglia get ready, set...

Learn More Learn More


Copyright 2014 Regenesance